TCG Crossover Management, LLC

Name: TCG Crossover Management, LLC: Form 13F holdings for the quarter ended 2026-06-30
Creator: Listed

An institutional investment manager in PALO ALTO, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1839948.

Share this page

Link

Story card, 1080 × 1920

Reported value$4.16bn
Positions54

Holdings: 54 positions

The filing on sec.gov

As filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.

TCG Crossover Management, LLC, holdings
Issuer	Class	CUSIP	Reported value$m	Weight	Shares	Change on the quarter before
Abivax SA American Depositary SharesABVX	COMM	00370M103	801	19.2%	6,007,834	Reduced−473,251
Tango Therapeutics IncTNGX	COMM	87583X109	284	6.8%	9,081,201	Reduced−1,449,870
CG Oncology IncCGON	COMM	156944100	261	6.3%	3,670,206	Unchanged
Cogent Biosciences IncCOGT	COMM	19240Q201	188	4.5%	4,854,436	Reduced−92,458
Immunovant IncIMVT	COMM	45258J102	172	4.1%	4,457,988	Unchanged
Spyre Therapeutics IncSYRE	COMM	00773J202	169	4.1%	1,900,582	Unchanged
Dianthus Therapeutics IncDNTH	COMM	252828108	163	3.9%	1,676,624	Unchanged
Mirum Pharmaceuticals IncMIRM	COMM	604749101	124	3.0%	1,062,049	Unchanged
ZAI Lab Ltd-AdrZLAB	ADRS	98887Q104	117	2.8%	6,137,627	New+6,137,627
Amylyx Pharmaceuticals IncAMLX	COMM	03237H101	112	2.7%	6,243,812	Unchanged
Monte Rosa Therapeutics IncGLUE	COMM	61225M102	112	2.7%	4,622,151	Unchanged
Biocryst Pharmaceuticals IncBCRX	COMM	09058V103	110	2.6%	11,020,968	Unchanged
VOR Biopharma IncVOR	COMM	929033207	104	2.5%	5,673,078	Unchanged
Tyra Biosciences IncTYRA	COMM	90240B106	104	2.5%	3,248,980	Unchanged
Dyne Therapeutics IncDYN	COMM	26818M108	103	2.5%	4,615,144	Unchanged
Disc Medicine IncIRON	COMM	254604101	98.1	2.4%	1,341,862	Unchanged
Relay Therapeutics IncRLAY	COMM	75943R102	80.0	1.9%	4,273,356	Unchanged
Savara IncSVRA	COMM	805111101	76.2	1.8%	12,362,205	Unchanged
Aura Biosciences IncAURA	COMM	05153U107	67.7	1.6%	9,533,333	New+9,533,333
Revolution Medicines IncRVMD	COMM	76155X100	63.8	1.5%	340,899	Reduced−235,574
First Tracks BiotherapeuticsTRAX	COMM	337185102	58.3	1.4%	2,895,304	New+2,895,304
Kodiak Sciences IncKOD	COMM	50015M109	56.3	1.4%	1,445,538	Unchanged
Avalo Therapeutics IncAVTX	COMM	05338F306	55.8	1.3%	3,017,120	Added+2,278,737
LB Pharmaceuticals IncLBRX	COMM	50180M108	47.0	1.1%	1,447,310	Reduced−392,179
Century Therapeutics IncIPSC	COMM	15673T100	43.4	1.0%	17,754,430	Unchanged
Tectonic Therapeutic IncTECX	COMM	878972108	41.4	1.0%	1,204,891	Unchanged
Xencor IncXNCR	COMM	98401F105	39.5	0.9%	2,452,138	Unchanged
Surrozen IncSRZN	COMM	86889P208	38.2	0.9%	1,473,101	Unchanged
Editas Medicine IncEDIT	COMM	28106W103	36.0	0.9%	11,111,111	New+11,111,111
MBX Biosciences IncMBX	COMM	55287L101	35.9	0.9%	650,000	Unchanged
Pharvaris BV	COMM	N69605108	34.9	0.8%	1,008,229	New+1,008,229
Silence Therapeutics plcSLN	ADRS	82686Q101	33.3	0.8%	3,033,560	Unchanged
Inflarx N V	COMM	N44821101	32.5	0.8%	14,500,000	New+14,500,000
Altimmune IncALT	COMM	02155H200	30.4	0.7%	10,000,000	New+10,000,000
Janux Therapeutics IncJANX	COMM	47103J105	27.5	0.7%	1,789,617	Unchanged
Perspective Therapeutics IncCATX	COMM	46489V302	27.0	0.6%	7,915,567	Unchanged
Agomab Therapeutics NVAGMB	ADRS	00860C102	26.7	0.6%	2,053,233	Unchanged
Biohaven Ltd	COMM	G1110E107	26.5	0.6%	1,779,952	Reduced−2,851,365
Aktis Oncology IncAKTS	COMM	01021M104	22.5	0.5%	696,560	New+696,560
Alector IncALEC	COMM	014442107	20.1	0.5%	10,000,000	Unchanged
Forte Biosciences Inc	COMM	34962G208	19.6	0.5%	920,000	New+920,000
Monopar Therapeutics IncMNPR	COMM	61023L207	18.8	0.5%	203,327	Added+71,224
Ocular Therapeutix IncOCUL	COMM	67576A100	16.2	0.4%	1,647,752	Unchanged
ADC Therapeutics SA	COMM	H0036K147	12.2	0.3%	11,390,175	Unchanged
ALX Oncology Holdings IncALXO	COMM	00166B105	11.7	0.3%	5,655,487	Reduced−7,356,362
Entrada Therapeutics IncTRDA	COMM	29384C108	7.8	0.2%	1,060,230	Reduced−1,227,270
Cullinan Therapeutics IncCGEM	COMM	230031106	7.4	0.2%	406,786	Unchanged
Arvinas Holding Co LLCARVN	COMM	04335A105	5.9	0.1%	707,098	Reduced−1,680,363
Korro Bio IncKRRO	COMM	500946108	5.5	0.1%	416,301	Unchanged
Research Alliance Corp CL a	COMM	G75226103	5.4	0.1%	500,000	New+500,000
Leonabio IncLONA	COMM	04746L203	4.3	0.1%	464,398	Unchanged
Jatt II Acquisition Corp	COMM	G50765109	2.3	<0.1%	200,000	New+200,000
Context Therapeutics IncCNTX	COMM	21077P108	1.5	<0.1%	2,682,696	Unchanged
Eikon Therapeutics IncEIKN	COMM	282564103	0.5	<0.1%	37,902	New+37,902

Sold out: 7 positions

Held at the end of the quarter before and not reported this quarter.

TCG Crossover Management, LLC, positions sold out
Issuer	Class	CUSIP	Weight	Change on the quarter before
Centessa Pharmaceuticals plc	ADRS	152309100	0.0%	Sold out−4,286,480
Fulcrum Therapeutics IncFULC	COMM	359616109	0.0%	Sold out−5,250,000
Liquidia Technologies IncLQDA	COMM	53635D202	0.0%	Sold out−403,048
Structure Therapeutics IncGPCR	ADRS	86366E106	0.0%	Sold out−140,411
Upstream Bio IncUPB	COMM	91678A107	0.0%	Sold out−181,063
Urogen Pharma Ltd	COMM	M96088105	0.0%	Sold out−405,365
Vistagen Therapeutics IncVTGN	COMM	92840H400	0.0%	Sold out−2,676,580

Source: SEC EDGAR, Form 13F-HR, accession 0001214659-26-010290 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.